BCBusiness
Some of the biggest pharmaceutical companies in the world are putting big money into developing a class of drugs that many hope will revolutionize the treatment of today’s most resilient diseases. RNA-interference drugs are designed to prevent the body from producing certain disease-causing proteins by selectively disrupting the mechanism that creates them in the first place: RNA.
Burnaby-based Tekmira has made itself indispensable in this field by developing a technique to deliver RNA-interference drugs into the body. Some top names in the pharmaceutical field are licensing this technology, including Anylam and Roche. The money from these contracts is helping support Tekmira’s own drug-development work. A cholesterol-controlling drug cleared its Phase-1 clinical trial in January, and a cancer drug is expected to enter Phase-1 trials this year.
BCBusiness celebrates the bold ideas, fearless founders, innovative leaders and game-changing companies driving British Columbia’s economy forward. We deliver insightful and impactful storytelling about the power players in B.C.’s business community to a connected audience, all with a deep love of the place we call home.
Get the latest headlines delivered to your inbox 3 times a week, and you’ll be entered to win a pair of Kanto’s newest compact desktop speakers—Uki in the colour “Chalk,” as well as a pair of SU2 stands. Prize value is $330 CAD. Each newsletter subscription = 1 entry. Giveaway closes December 12. The winner will be contacted by an @canadawide.com email. Contest is only open to Canadian residents, excluding Quebec.